WO2002068650A3 - Modified and stabilized gdf propeptides and uses thereof - Google Patents

Modified and stabilized gdf propeptides and uses thereof Download PDF

Info

Publication number
WO2002068650A3
WO2002068650A3 PCT/US2002/003467 US0203467W WO02068650A3 WO 2002068650 A3 WO2002068650 A3 WO 2002068650A3 US 0203467 W US0203467 W US 0203467W WO 02068650 A3 WO02068650 A3 WO 02068650A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
muscle
modified
propeptides
obesity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/003467
Other languages
French (fr)
Other versions
WO2002068650A2 (en
WO2002068650B1 (en
Inventor
Neil M Wolfman
Soo Peang Khor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0207110-0A priority Critical patent/BR0207110A/en
Priority to MXPA03007063A priority patent/MXPA03007063A/en
Priority to CA002437218A priority patent/CA2437218A1/en
Priority to EP02709366A priority patent/EP1397492B1/en
Priority to NZ527286A priority patent/NZ527286A/en
Priority to JP2002568744A priority patent/JP4280071B2/en
Priority to HK04104973.9A priority patent/HK1062457B/en
Priority to AU2002243852A priority patent/AU2002243852B2/en
Priority to DE60219006T priority patent/DE60219006T2/en
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to DK02709366T priority patent/DK1397492T3/en
Publication of WO2002068650A2 publication Critical patent/WO2002068650A2/en
Priority to NO20033456A priority patent/NO333427B1/en
Anticipated expiration legal-status Critical
Publication of WO2002068650A3 publication Critical patent/WO2002068650A3/en
Publication of WO2002068650B1 publication Critical patent/WO2002068650B1/en
Priority to CY20071100719T priority patent/CY1106629T1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasteing syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity) and bone degenerative diseases (such as osteoporosis).
PCT/US2002/003467 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof Ceased WO2002068650A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DE60219006T DE60219006T2 (en) 2001-02-08 2002-02-08 Modified and stabilized GDF propeptides and their uses
CA002437218A CA2437218A1 (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof
EP02709366A EP1397492B1 (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof
NZ527286A NZ527286A (en) 2001-02-08 2002-02-08 Modified and stabilized GDF propeptides and uses thereof
JP2002568744A JP4280071B2 (en) 2001-02-08 2002-02-08 Modified and stabilized GDF propeptides and uses thereof
HK04104973.9A HK1062457B (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof
AU2002243852A AU2002243852B2 (en) 2001-02-08 2002-02-08 Modified and stabilized GDF propeptides and uses thereof
BR0207110-0A BR0207110A (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof
DK02709366T DK1397492T3 (en) 2001-02-08 2002-02-08 Modified and stabilized GDF propeptides and their applications
MXPA03007063A MXPA03007063A (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof.
NO20033456A NO333427B1 (en) 2001-02-08 2003-08-04 Modified GDF-8 propeptides, process for their preparation and use, nucleic acid molecule encoding modified GDF-8 propeptide, and pharmaceutical composition
CY20071100719T CY1106629T1 (en) 2001-02-08 2007-05-29 MODIFIED AND STABILIZED GDF PROPEPTIDES AND USES THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26750901P 2001-02-08 2001-02-08
US60/267,509 2001-02-08

Publications (3)

Publication Number Publication Date
WO2002068650A2 WO2002068650A2 (en) 2002-09-06
WO2002068650A3 true WO2002068650A3 (en) 2003-08-21
WO2002068650B1 WO2002068650B1 (en) 2004-01-08

Family

ID=23019083

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003467 Ceased WO2002068650A2 (en) 2001-02-08 2002-02-08 Modified and stabilized gdf propeptides and uses thereof

Country Status (22)

Country Link
US (6) US7202210B2 (en)
EP (1) EP1397492B1 (en)
JP (3) JP4280071B2 (en)
AR (1) AR032567A1 (en)
AT (1) ATE357519T1 (en)
AU (1) AU2002243852B2 (en)
BR (1) BR0207110A (en)
CA (2) CA2437218A1 (en)
CL (1) CL2009000648A1 (en)
CY (1) CY1106629T1 (en)
DE (1) DE60219006T2 (en)
DK (1) DK1397492T3 (en)
ES (1) ES2284828T3 (en)
MX (1) MXPA03007063A (en)
NO (1) NO333427B1 (en)
NZ (2) NZ550297A (en)
PL (2) PL212078B1 (en)
PT (1) PT1397492E (en)
SG (2) SG165982A1 (en)
TW (2) TW200526779A (en)
WO (1) WO2002068650A2 (en)
ZA (2) ZA200508954B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280214B2 (en) 2009-11-05 2019-05-07 Hoffmann-La Roche Inc. Glycosylated repeat-motif-molecule conjugates

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
BR0307871A (en) * 2002-02-21 2005-04-12 Wyeth Corp Folistatin Domain-Containing Proteins
EP1572909A4 (en) * 2002-02-21 2007-06-06 Wyeth Corp A follistatin domain containing protein
MXPA05002968A (en) * 2002-09-16 2005-09-08 Univ Johns Hopkins Metalloprotease activation of myostatin, and methods of modulating myostatin activity.
AR047392A1 (en) 2002-10-22 2006-01-18 Wyeth Corp NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
RU2322261C2 (en) * 2003-06-02 2008-04-20 Уайт Applying myostatic inhibitors (gdf8) in combination with corticosteroids for treating nervous-muscular diseases
JP2008507288A (en) * 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ActRII receptor polypeptides, methods, and compositions
AU2005272646A1 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI384069B (en) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals Production of polypeptides
US8088508B2 (en) 2005-01-31 2012-01-03 Panasonic Corporation Thermal battery
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
JP2008537777A (en) * 2005-03-23 2008-09-25 ワイス Detection of immune response to GDF-8 modulator
EP1864138A2 (en) * 2005-03-23 2007-12-12 Wyeth Detection of gdf-8 modulating agents
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
ES2649983T3 (en) 2005-11-23 2018-01-16 Acceleron Pharma, Inc. Activin-ActRIIa antagonists in their use to promote bone growth
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
ES2444695T3 (en) * 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polynucleotides and polypeptides involved in cancer
SI2049664T1 (en) 2006-08-11 2012-04-30 Prosensa Technologies Bv Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN104524548A (en) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 Activin-ACTRII antagonists and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
MX2009008222A (en) * 2007-02-01 2009-10-12 Acceleron Pharma Inc Activin-actriia antagonists and uses for treating or preventing breast cancer.
TW201803890A (en) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 Variants derived from ActRIIB and their uses
EA018221B1 (en) 2007-02-09 2013-06-28 Акселерон Фарма Инк. ACTIVIN-ActRIIa ANTAGONISTS AND USES FOR PROMOTING BONE GROWTH IN CANCER PATIENTS
WO2009008727A2 (en) * 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
CA2693742A1 (en) * 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
CN101861161B (en) 2007-09-18 2017-04-19 阿塞勒隆制药公司 ACTIN-ACTRIIA ANTAGONISTS AND USE FOR REDUCING OR INHIBITING FSH SECRETION
ES2639852T3 (en) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Means and methods to counteract muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
WO2009099326A1 (en) * 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
CA2723987C (en) 2008-05-14 2019-06-11 Agriculture Victoria Services Pty Ltd Use of angiogenin or angiogenin agonists for treating diseases and disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN102131822A (en) * 2008-06-26 2011-07-20 阿塞勒隆制药公司 Methods for dosing activin-actriia antagonist and monitoring of treated patients
TW201803586A (en) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 Use GDF traps to increase red blood cell levels
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
EP2421971B1 (en) 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
KR20120049214A (en) 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 Methods for increasing thermogenic adipocytes
KR20180026795A (en) 2009-06-12 2018-03-13 악셀레론 파마 인코포레이티드 TRUNCATED ActRIIB-FC FUSION PROTEINS
EP3202459B1 (en) * 2009-09-09 2021-04-14 Acceleron Pharma Inc. Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content
AU2010315245B2 (en) * 2009-11-03 2016-11-03 Acceleron Pharma Inc. Methods for treating fatty liver disease
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2011078672A1 (en) 2009-12-24 2011-06-30 Prosensa Technologies B.V. Molecule for treating an inflammatory disorder
JP2013535981A (en) 2010-08-20 2013-09-19 ワイス・エルエルシー Cell culture of growth factor-free compatible cells
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
SI3173427T1 (en) 2011-03-31 2019-08-30 ADC Therapeutics SA, Antibodies to the kidney-bound antigen 1 and antigen-binding fragments thereof
RU2663794C2 (en) 2011-10-21 2018-08-09 Пфайзер Инк. Adding iron to improve cell culture
KR102102239B1 (en) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 Method for treating breast cancer
NZ627896A (en) 2012-01-27 2016-11-25 Biomarin Technologies B V Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
WO2014000042A1 (en) * 2012-06-27 2014-01-03 Prince Henry's Institute Of Medical Research COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
JP2015531244A (en) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Mammalian cell culture method for producing protein
CN104968801B (en) * 2012-10-24 2021-06-15 细胞基因公司 Biomarkers for the treatment of anemia
HK1214504A1 (en) 2012-10-24 2016-07-29 细胞基因公司 Methods for treating anemia
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (en) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. Compositions and methods of use in treating metabolic disorders
WO2014119753A1 (en) * 2013-01-31 2014-08-07 学校法人 東京薬科大学 Myostatin-inhibiting peptide
ES2924479T3 (en) 2013-04-08 2022-10-07 Harvard College Compositions for rejuvenating skeletal muscle stem cells
US20160220640A1 (en) * 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
US9862752B2 (en) * 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
CN104725513A (en) * 2013-12-20 2015-06-24 中国科学院上海生命科学研究院 Fusion protein and its use in multiple sclerosis treatment
CN114699529A (en) 2014-06-13 2022-07-05 阿塞勒隆制药公司 Methods and compositions for treating ulcers
AU2015296640B2 (en) 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
JP2018501307A (en) 2014-12-03 2018-01-18 セルジーン コーポレイション Activin-ActRII antagonist and use for treating anemia
CA3010799A1 (en) * 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
WO2020132647A1 (en) 2018-12-21 2020-06-25 Northwestern University Use of annexins in preventing and treating muscle membrane injury
WO2020139977A1 (en) 2018-12-26 2020-07-02 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024058A2 (en) * 1997-11-07 1999-05-20 Genetics Institute, Inc. Neuronal uses of bmp-11
WO1999045949A2 (en) * 1998-03-09 1999-09-16 Genetics Institute, Inc. Use of follistatin to modulate gdf-8 and bmp-11
WO1999056768A1 (en) * 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
WO2000011163A1 (en) * 1998-08-20 2000-03-02 Regeneron Pharmaceuticals, Inc. Dcr5, a bmp-binding protein, and applications thereof
WO2000043781A2 (en) * 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
WO2002009641A2 (en) * 2000-07-27 2002-02-07 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3382562D1 (en) 1982-09-24 1992-06-25 Us Health ANIMAL TISSUE RECOVERY.
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
NZ210699A (en) 1984-01-04 1989-06-28 Int Genetic Eng Isolation of an osteogenic protein of the p3 immunologically related family
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
CA1341617C (en) 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
UA39161C2 (en) 1984-07-06 2001-06-15 Новартіс Аг Recombinant protein of GM-CSF for increase in productION of granylocytes and macrophages by patients, vector and cdna coding it
EP0169016B2 (en) 1984-07-16 2004-04-28 Celtrix Pharmaceuticals, Inc. Polypeptide cartilage-inducing factors found in bone
US4740587A (en) 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
NZ217727A (en) 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US5215893A (en) 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4737578A (en) 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5187076A (en) 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
AU645244B2 (en) 1988-04-08 1994-01-13 Genetics Institute, Llc Bone and cartilage inductive compositions
US5071834A (en) 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
DK0429570T3 (en) 1989-03-28 1998-04-27 Genetics Inst Osteoinducing preparations
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
CA2020729A1 (en) 1989-07-19 1991-01-20 Michael C. Kiefer Bone morphogenetic protein
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5166190A (en) 1990-01-08 1992-11-24 Genentech, Inc. Method for increasing fertility in males
WO1991018098A1 (en) 1990-05-16 1991-11-28 Genetics Institute, Inc. Bone and cartilage inductive proteins
EP0550625B1 (en) 1990-09-26 2003-11-05 Genetics Institute, LLC Bmp-5 derivatives
WO1992009697A1 (en) 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
WO1992020371A1 (en) 1991-05-10 1992-11-26 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
US6162896A (en) * 1991-05-10 2000-12-19 The Salk Institute For Biological Studies Recombinant vertebrate activin receptors
EP0592562B1 (en) 1991-06-25 1999-01-07 Genetics Institute, Inc. Bmp-9 compositions
CA2580812A1 (en) * 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
US5171579A (en) 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
PT653942E (en) 1992-07-31 2003-11-28 Curis Inc REGENERATION AND REPARATION OF MORPHOGENES INDUCED NERVES
DK0690873T3 (en) * 1993-03-19 2003-09-29 Univ Johns Hopkins Med Growth Differentiation Factor-8
US6465239B1 (en) 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US6673534B1 (en) 1995-10-26 2004-01-06 The Johns Hopkins University School Of Medicine Methods for detection of mutations in myostatin variants
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US20030074680A1 (en) 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
WO1994026892A1 (en) 1993-05-12 1994-11-24 Genetics Institute, Inc. Bmp-11 compositions
EP1716864A1 (en) * 1993-08-26 2006-11-02 Genetics Institute, LLC Neural regeneration using home bone morphogenetic proteins
US7332575B2 (en) 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
EP1574577A3 (en) * 1994-07-08 2006-06-14 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US5466190A (en) * 1994-07-25 1995-11-14 Deere & Company Precleaner for a cleaning shoe
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
JPH10262688A (en) * 1994-11-30 1998-10-06 Univ Rockefeller Modulators of body weight, corresponding nucleic acids and proteins, and their diagnostic and therapeutic uses
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
EP0894004B2 (en) 1996-03-22 2007-02-21 Curis, Inc. Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
US6696557B1 (en) * 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
AR008077A1 (en) * 1996-07-26 1999-12-09 Talarico Salinas Laura Beatriz A FUSION POLYPEPTIDE OR A SALT OF THE SAME, ITS USE, A PROCESS TO PREPARE THEM, A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM, AND A VECTOR.
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
AU756620B2 (en) * 1997-07-14 2003-01-16 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
AU8666398A (en) 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
GB2345397B (en) * 1997-08-19 2001-10-31 Citizen Watch Co Ltd Piezoelectric vibrator
JP2001513982A (en) 1997-08-29 2001-09-11 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Follistatin-3
AU1390999A (en) 1997-11-10 1999-05-31 Johns Hopkins University School Of Medicine, The Methods for detection of mutations in myostatin variants
CA2319703C (en) 1998-02-05 2005-09-20 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
AU782493B2 (en) * 1999-06-01 2005-08-04 Curis, Inc. Polymer conjugates of hedgehog proteins and uses
TR200400621T2 (en) 1999-07-20 2004-08-23 Pharmexa A/S A method for downregulating GDF-8 activity.
WO2001064888A2 (en) 2000-02-29 2001-09-07 Zymogenetics, Inc. Kunitz domain polypeptide zkun8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL350983A1 (en) * 2001-11-30 2003-06-02 Advanced Digital Broadcast Ltd Method of scanning a high-frequency signal band and apparatus therefor
BR0307871A (en) 2002-02-21 2005-04-12 Wyeth Corp Folistatin Domain-Containing Proteins
EP1572909A4 (en) 2002-02-21 2007-06-06 Wyeth Corp A follistatin domain containing protein
MXPA05002968A (en) * 2002-09-16 2005-09-08 Univ Johns Hopkins Metalloprotease activation of myostatin, and methods of modulating myostatin activity.
AR047392A1 (en) 2002-10-22 2006-01-18 Wyeth Corp NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
BR0317538A (en) 2002-12-20 2005-11-29 Amgen Inc Binding agent, polynucleotide sequence, expression vector, host cell, pharmaceutical composition, and methods of inhibiting myostatin activity, increasing lean muscle mass and lean to fat ratio, treating muscle wasting disease is a myostatin-related metabolic disorder in an individual, detecting and measuring myostatin in a sample, and diagnosing a myostatin-related disorder in an individual
RU2322261C2 (en) 2003-06-02 2008-04-20 Уайт Applying myostatic inhibitors (gdf8) in combination with corticosteroids for treating nervous-muscular diseases
EP1864138A2 (en) 2005-03-23 2007-12-12 Wyeth Detection of gdf-8 modulating agents
JP2008537777A (en) 2005-03-23 2008-09-25 ワイス Detection of immune response to GDF-8 modulator

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024058A2 (en) * 1997-11-07 1999-05-20 Genetics Institute, Inc. Neuronal uses of bmp-11
WO1999045949A2 (en) * 1998-03-09 1999-09-16 Genetics Institute, Inc. Use of follistatin to modulate gdf-8 and bmp-11
WO1999056768A1 (en) * 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
WO2000011163A1 (en) * 1998-08-20 2000-03-02 Regeneron Pharmaceuticals, Inc. Dcr5, a bmp-binding protein, and applications thereof
WO2000043781A2 (en) * 1999-01-21 2000-07-27 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
WO2002009641A2 (en) * 2000-07-27 2002-02-07 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHU X. ET AL.: "Dominant negative myostatin produces hypertrophy without hyperplasia in muscle", FEBS LETTERS, vol. 474, no. 1, 26 May 2000 (2000-05-26), pages 71 - 75, XP004337183, ISSN: 0014-5793 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280214B2 (en) 2009-11-05 2019-05-07 Hoffmann-La Roche Inc. Glycosylated repeat-motif-molecule conjugates

Also Published As

Publication number Publication date
US8222384B2 (en) 2012-07-17
US8710025B2 (en) 2014-04-29
DE60219006T2 (en) 2007-12-13
JP2006001938A (en) 2006-01-05
JP2009091366A (en) 2009-04-30
HK1062457A1 (en) 2004-11-05
AR032567A1 (en) 2003-11-12
NZ550297A (en) 2008-04-30
EP1397492B1 (en) 2007-03-21
PL212078B1 (en) 2012-08-31
CA2674673A1 (en) 2002-09-06
US7737116B2 (en) 2010-06-15
EP1397492A2 (en) 2004-03-17
WO2002068650A2 (en) 2002-09-06
US20070149455A1 (en) 2007-06-28
US20100305194A1 (en) 2010-12-02
CY1106629T1 (en) 2012-01-25
NO20033456D0 (en) 2003-08-04
ZA200508954B (en) 2006-07-26
NZ527286A (en) 2006-11-30
ES2284828T3 (en) 2007-11-16
PL207202B1 (en) 2010-11-30
TWI329129B (en) 2010-08-21
JP4280071B2 (en) 2009-06-17
AU2002243852B2 (en) 2007-08-16
WO2002068650B1 (en) 2004-01-08
CL2009000648A1 (en) 2009-06-12
NO333427B1 (en) 2013-06-03
CA2437218A1 (en) 2002-09-06
PT1397492E (en) 2007-06-15
MXPA03007063A (en) 2004-10-15
JP5013618B2 (en) 2012-08-29
NO20033456L (en) 2003-10-06
PL372888A1 (en) 2005-08-08
JP2005507637A (en) 2005-03-24
US7560441B2 (en) 2009-07-14
DE60219006D1 (en) 2007-05-03
ATE357519T1 (en) 2007-04-15
ZA200306064B (en) 2006-02-22
US20120252884A1 (en) 2012-10-04
US20030104406A1 (en) 2003-06-05
TW200526779A (en) 2005-08-16
SG165982A1 (en) 2010-11-29
SG187989A1 (en) 2013-03-28
BR0207110A (en) 2005-08-16
US20140228289A1 (en) 2014-08-14
US7202210B2 (en) 2007-04-10
US20070238683A1 (en) 2007-10-11
DK1397492T3 (en) 2007-07-09

Similar Documents

Publication Publication Date Title
WO2002068650A3 (en) Modified and stabilized gdf propeptides and uses thereof
Hunter et al. Fifth metacarpal fractures in a compensation clinic population: a report on one hundred and thirty-three cases
AU2003273967A1 (en) Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases
EP2168962A3 (en) Phenylacetamides and their use as glucokinase modulators
IL151791A (en) Use of a dry powder composition comprising microparticles of glycopyrrolate for preparation of a pharmaceutical composition for treating a disease of the airways
CA2403902A1 (en) Malonamic acids and derivatives thereof as thyroid receptor ligands
WO2003072715A8 (en) Gasp1: a follistatin domain containing protein
SI2527315T1 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
WO2003039344A3 (en) Methods and compositions for correction of cardiac conduction disturbances
WO2003027248A8 (en) Antibody inhibitors of gdf-8 and uses thereof
WO2003072714A3 (en) Follistatin domain containing proteins
WO2003059934A3 (en) Albumin fusion proteins
MXPA05011524A (en) Substituted carboxylic acids.
WO2005039643A3 (en) In vivo gene therapy of parkinson's disease
EP1273269A3 (en) Implantable screw for stabilising an articulated joint or a bone fracture
WO2005019256A3 (en) Muteins of tear lipocalin
WO2004099171A3 (en) Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
EP0797999A3 (en) Formulations of obesity protein
WO2003099992A3 (en) Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
WO2001003719A3 (en) Combination therapy for conditions leading to bone loss
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000003610A8 (en) Method for producing an iodinated food product
WO2002070546A3 (en) Modified derivatives of cck-8
EP1790726A3 (en) Modified and stabilized GDF propeptides and uses thereof
WO2008019062A3 (en) Polypeptide derivatives of parathyroid hormone (pth)

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2437218

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 527286

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003/06064

Country of ref document: ZA

Ref document number: 2002568744

Country of ref document: JP

Ref document number: 200306064

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007063

Country of ref document: MX

Ref document number: 372888

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2002243852

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002709366

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

B Later publication of amended claims

Effective date: 20030423

WWP Wipo information: published in national office

Ref document number: 2002709366

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002709366

Country of ref document: EP